AREC vs. SCLP, ORPH, REDX, ETX, TRX, SBTX, COS, C4XD, DDDD, and OBI
Should you be buying Arecor Therapeutics stock or one of its competitors? The main competitors of Arecor Therapeutics include Scancell (SCLP), Open Orphan (ORPH), Redx Pharma (REDX), e-therapeutics (ETX), Tissue Regenix Group (TRX), SkinBioTherapeutics (SBTX), Collagen Solutions plc (COS.L) (COS), C4X Discovery (C4XD), 4D pharma (DDDD), and Ondine Biomedical (OBI). These companies are all part of the "biotechnology" industry.
Arecor Therapeutics vs.
Scancell (LON:SCLP) and Arecor Therapeutics (LON:AREC) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk, community ranking, media sentiment and dividends.
46.5% of Scancell shares are held by institutional investors. Comparatively, 44.1% of Arecor Therapeutics shares are held by institutional investors. 5.0% of Scancell shares are held by company insiders. Comparatively, 25.3% of Arecor Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Scancell has higher revenue and earnings than Arecor Therapeutics. Scancell is trading at a lower price-to-earnings ratio than Arecor Therapeutics, indicating that it is currently the more affordable of the two stocks.
Scancell has a net margin of 0.00% compared to Arecor Therapeutics' net margin of -176.89%. Arecor Therapeutics' return on equity of -94.76% beat Scancell's return on equity.
Scancell received 187 more outperform votes than Arecor Therapeutics when rated by MarketBeat users.
Scancell has a beta of 0.35, indicating that its stock price is 65% less volatile than the S&P 500. Comparatively, Arecor Therapeutics has a beta of -0.18, indicating that its stock price is 118% less volatile than the S&P 500.
In the previous week, Scancell had 1 more articles in the media than Arecor Therapeutics. MarketBeat recorded 1 mentions for Scancell and 0 mentions for Arecor Therapeutics. Scancell's average media sentiment score of 0.00 equaled Arecor Therapeutics'average media sentiment score.
Summary
Scancell beats Arecor Therapeutics on 9 of the 13 factors compared between the two stocks.
Get Arecor Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AREC and its competitors with MarketBeat's FREE daily newsletter.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Arecor Therapeutics Competitors List
Related Companies and Tools
This page (LON:AREC) was last updated on 1/21/2025 by MarketBeat.com Staff
